Leveraging Real World Evidence, Registries, and Decentralized Trials for Next Generation Innovation
Enabling Successful Trial Recruitment through Centralized Technology Platforms
A Controversial Issue in Clinical Investigation for Rare Disease Drug Development
US Biosimilar Market
Data Governance in Life Sciences
EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Sustainable Innovation in Biopharma: Aligning Therapeutic Progress with Environmental Responsibility
To genuinely align RD with environmental responsibility biopharma organisations must embrace systemic structural and cultural transformations
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
Applying CPCA: A Risk Based Framework for Nitrosamine Control in Pharmaceuticals
NNitrosamines are a structurally diverse class of potent mutagenic carcinogens formed when nitrosating species react with amines often via hydroxylation to DNA reactive intermediates Even at trace levels long term exposure in chronically administered medicines can translate into a measurable incremental lifetime cancer risk The discovery of nitrosamines in valsartan and other sartan products was...
-
Techno Trends
Case Western Reserve Scientists Discover Novel Molecular Target for Parkinson’s Disease
Researchers at Case Western Reserve University have discovered a new biochemical pathway that could lead to treatments targeting the underlying causes of Parkinsons disease
-
Projects
PharmaEssentia Invests $46M to Expand U.S. Manufacturing Footprint for BESREMi®
PharmaEssentia Corporation has announced plans to establish a new wholly owned manufacturing subsidiary in Puerto Rico The US million investment aims to expand the production of BESREMi
-
Research Insights
Controllable protein design via autoregressive direct coupling analysis conditioned on principal components
We present FeatureDCA a statistical framework for protein sequence modeling and generation that extends Direct Coupling Analysis DCA
-
White Papers
Accelerating In-Vitro Antibody Discovery with Artificial Intelligence
Antibodies have transformed modern medicine reshaping treatment paradigms across autoimmune disorders oncology and infectious diseases As one of the most versatile and successful therapeutic modalities
TOP ARTICLES
-
1
Is Digital Transformation the Key to Pharma's Operational Excellence?
Kate Williamson
The pharmaceutical industry is undergoing a profound shift with the adoption of digital transformation, offering opportunities for operational excellence. Key aspects include data-driven decision-maki...
-
2
Personalized Medicine and Genomics: Charting a New Course in Drug Innovation
Kate Williamson
These are personalized medicine, which can be attributed to the enhancements in genomics as treatment procedures that are formulated according to people’s genetic make-up offers enhanced efficac...
-
3
Evolving Trends and Strategies in Pharmaceutical Marketing: Focus on the American Market
Kate Williamson
This exploration delves into evolving trends and strategies in pharmaceutical marketing, with a focus on the dynamic American market. From digital transformation and patient-centric approaches to data...
-
4
Harnessing Digital Biomarkers and Wearables: Transforming Clinical Research
Kate Williamson
Digital biomarkers and wearables are revolutionizing clinical research by providing real-time data on patients' health. They offer insights into physiological and behavioral changes, and improve t...
-
5
Biotech Boom: How Startups are Driving U.S. Pharma Growth
Kate Williamson
An array of biotech start-ups in America are transforming the pharmacovigilance industry through novel technologies such as CRISPR, Artificial Intelligence, and Precision Medicine. Supported by fundin...
press releasesRead more...
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)
Affinia Therapeutics Affinia an innovative gene therapy company with a pipeline of firstinclass andor bestinclass adenoassociated virus AAV gene therapies initially for devastating cardiovascular diseases
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients
Vasomune Therapeutics Inc a clinicalstage biopharmaceutical company today announced US Food and Drug Administration FDA clearance of the Investigational New Drug IND application to develop Pegevongitide AV
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA and funds managed by Blackstone Life Sciences BXLS today announced a million strategic funding
Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs
Ono Pharmaceutical Co Ltd and Congruence Therapeutics today announced that they have expanded their existing multitarget research partnership through the execution of a new research collaboration for two additional programs
Events Read more...
09 - 11
Mar 20268th International Conference
8105, Suite 112, Rasor Blvd, Plano TX 75024, USA
10 - 12
Mar 2026Bioprocessing Summit Europe 2026
InterContinental Barcelona, Spain
10 - 10
Mar 2026Age of AI Europe 2026
Institute of Engineering and Technology (IET) London,UK
10 - 12
Mar 2026Healthcare & Hospi.Log Asia 2026
Singapore
11 - 12
Mar 20269th Annual Pharma Regulatory Summit 2026
Mumbai, India
16 - 17
Mar 2026Pharma USA 2026
Philadelphia, PA , USA
16 - 18
Mar 2026Pharmaceutics and Novel Drug
Kuala Lumpur, Malaysia
16 - 18
Mar 2026Advanced Clinical Research
Kuala Lumpur, Malaysia
LATEST NEWSRead more...
FDA Greenlights Boehringer's HERNEXEOS as First Targeted Therapy for HER2-Mutant NSCLC
The US FDA has approved Boehringer Ingelheims HERNEXEOS zongertinib tablets as the first targeted initial therapy for adults with advanced nonsmall cell lung cancer harboring HER ERBB tyrosine kinase domain activating mutations
INOVIO and Akeso Collaborate to Study New Combination Therapy for Glioblastoma
INOVIO and Akeso Inc have entered into a clinical trial collaboration and supply agreement to evaluate a new combination therapy for the treatment of Glioblastoma GBM an aggressive form of brain cancer
Sinopia Biosciences to Collaborate with Ono Pharmaceutical on Target Discovery for Rare Metabolic Disorders
Sinopia Biosciences Inc has announced a target discovery collaboration with Ono Pharmaceutical Co Ltd focused on a group of rare metabolic disorders The disorders remain undisclosed and are associated with significant unmet medical need
Vanda Receives FDA Grant for Formal Hearing on HETLIOZ® Application
Vanda Pharmaceuticals Inc has announced that the US Food and Drug Administration FDA has granted its request for a formal evidentiary public hearing regarding the proposed refusal to approve its supplemental
FDA Greenlights Boehringer Ingelheim's HERNEXEOS for HER2-Mutant NSCLC
The US FDA has approved Boehringer Ingelheims HERNEXEOS zongertinib tablets as the first targeted initial therapy for adults with advanced nonsmall cell lung cancer harboring HER ERBB tyrosine kinase domain activating mutations
PharmaEssentia Secures Japan Approval for High-Dose BESREMi® Regimen
PharmaEssentia Corporation has received approval in Japan for a highdose dosing regimen of BESREMi ropeginterferon alfab The approval was granted by Japans Ministry of Health Labour and Welfare and allows the updated dosing schedule to be included in the product label as an alternative option
